Zambon S.p.A.

ADBOSVA

pharmaceutical preparations for the treatment and cure of severe respiratory diseases, in particular for the treatment and cure of Bronchiolitis Obliterans Syndrome (BOS);

AERNAMIQ

Pharmaceutical preparations for prevention and treatment of diseases of the respiratory tract;Medical apparatus and instruments for the administration of medicinal substances for the prevention and treatment of diseases of the respiratory tract;

AIREGO

Pharmaceutical preparations for prevention and treatment of diseases of the respiratory tract;AIR EGO;Medical apparatus and instruments for the administration of medicinal substances for the prevention and treatment of diseases of the respiratory tract;

ARIZURANS

pharmaceutical preparations for the treatment and cure of severe respiratory diseases, in particular for the treatment and cure of Bronchiolitis Obliterans Syndrome (BOS);

AYLOMI

pharmaceutical preparations for the treatment of respiratory diseases and disorders;

EFABO

pharmaceutical preparations for the treatment of respiratory diseases and disorders;

EFFIHALER

Pharmaceutical products for treating respiratory diseases;Medical devices, namely, inhalers and nebulizers for administering medications for the treatment of respiratory diseases;

ELQIBRI

Pharmaceutical products for the prevention and cure of neurological diseases and disorders;

ENAYJY

pharmaceutical preparations for the treatment and cure of severe respiratory diseases, in particular for the treatment and cure of Bronchiolitis Obliterans Syndrome (BOS);

FIDEVRY

pharmaceutical preparations for the treatment of respiratory diseases and disorders;

FLUIMUCIL

pharmaceutical preparations; namely, antibiotics, antidotes, chemotherapeutics, and specialties for the respiratory system;

FLUIMUCIL

Pharmaceutical preparations, namely, antibiotics, antidotes, chemotherapeutics and specialties for the respiratory system;

FLUIMUCIL

PHARMACEUTICAL PREPARATIONS; NAMELY, ANTIBIOTICS, ANTIDOTES, CHEMOTHERAPEUTICS AND SPECIALTIES FOR THE RESPIRATORY SYSTEM;

FLUIMUCIL

Pharmaceutical preparations, namely, antibiotics, antidotes, chemotherapeutics and specialties for the respiratory system;

GLITISOL

pharmaceutical preparations; namely, antibiotics and chemotherapeutics;

HALMYZE

pharmaceutical preparations for the treatment of respiratory diseases and disorders;

MIDELVY

pharmaceutical preparations for the treatment of respiratory diseases and disorders;

MONUROL

antibiotics;

MYBEMO

pharmaceutical preparations for the treatment of respiratory diseases and disorders;MY BEMO;

MYCEMO

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

NIFURYL

CHEMOTHERAPEUTIC AGENT;

ONSTRYV

Pharmaceutical products for the prevention and cure of neurological diseases and disorders;

OVRINDO

Pharmaceutical preparations for prevention and treatment of diseases of the respiratory tract;Medical apparatus and instruments for the administration of medicinal substances for the prevention and treatment of diseases of the respiratory tract;

PROMIX

Pharmaceutical preparations and substances for the treatment of respiratory diseases sold only by prescription; antimicrobial pharmaceutical preparations and substances sold only by prescription; anti-infective pharmaceutical preparations and substances for the treatment of lung diseases sold only by prescription; all of the above-listed goods excluding dietary and nutritional supplements for use in athletic development, and excluding dietary food supplements sold to hospitals and patient care facilities;

SPEDIFEN

Pharmaceutical products, namely, anti-inflammatories, analgesics and anti-rheumatics;

TEQVEOLA

pharmaceutical preparations for the treatment and cure of severe respiratory diseases, in particular for the treatment and cure of Bronchiolitis Obliterans Syndrome (BOS);

TUVAZYTE

pharmaceutical preparations for the treatment and cure of severe respiratory diseases, in particular for the treatment and cure of Bronchiolitis Obliterans Syndrome (BOS);

XADAGO

Pharmaceutical products for the prevention and cure of neurological diseases and disorders;

YONAVAY

Pharmaceutical preparations for the prevention and cure of neurological diseases and disorders;

YOSTEDE

Pharmaceutical preparations for the prevention and cure of neurological diseases and disorders;

Z ZAMBON

Pharmaceutical and Medicinal Preparations for Human and Veterinary Use;

ZABLISH

pharmaceutical preparations for the treatment of respiratory diseases and disorders;

ZAMBON

LINE OF PHARMACEUTICAL AND MEDICINAL PREPARATIONS FOR HUMAN AND VETERINARY USE;

ZAMBON

Pharmaceutical, veterinary and sanitary preparations, for all purposes; dietetic substances adapted for medical use; food for babies; medical plasters; materials for medical, surgical and wound dressing; material for stopping teeth; dental wax;all-purpose disinfectants; preparations for destroying vermin; fungicides; and herbicides;

ZAMBON

The mark consists of a stylized depiction of a human head formed by white swirls and surrounded by white swirls on a blue rectangle appearing above a green block with the term Zambon in the bottom right corner with a white square around the letter Z.;Pharmaceutical products for the treatment of respiratory diseases;The color(s) blue, green and white is/are claimed as a feature of the mark.;